首页|期刊导航|Oncology Research|CDKN1A/p21 Influences the Survival and Expansion of Breast Cancer Stem Cells after Oxidative Damage

CDKN1A/p21 Influences the Survival and Expansion of Breast Cancer Stem Cells after Oxidative DamageOA

中文摘要

Objective:Breast cancer remains one of the most prevalent malignancies among women worldwide,and despite advances in therapy and treatment options,tumour relapse and metastasis remain major clinical challenges,largely driven by the breast cancer stem cells(BCSCs)niche that resists conventional treatments and regenerates tumours.In breast cancer,where approximately 30%of patients who initially respond to treatment ultimately relapse and die of metastatic disease,targeting BCSCs is critical for improving patient outcomes.Cyclin-dependent kinase inhibitor 1A/p21(CDKN1A/p21)is a multifunctional protein that is known primarily for its role in regulating the cell cycle in response to DNA damage.However,in this study,we aimed to explore the role of CDKN1A/p21 in the survival and expansion of BCSCs.Methods:We used three-dimensional in vitro models to assess the influence of CDKN1A/p21 expression on the survival of BCSCs both under basal conditions and after oxidative damage.Spatial transcriptomics analysis and chromatin immunoprecipitation-quantitative PCR(qPCR)were used to investigate the role of CDKN1A/p21 in the regulation and control of BCSC gene expression signatures.Results:We demonstrated that alterations in CDKN1A/p21 expression affect the ability of breast cancer cells to grow and survive after oxidative damage.Mechanistically,we found that CDKN1A/p21 directly binds to the promoter and regulates the expression of CD44,SPP1,and TMSB10,a combination gene signature that is associated with a greater probability of recurrence and metastasis in breast cancer patients.Conclusions:We propose that changes in gene regulation mediated by CDKN1A/p21 possibly contribute to cancer stem cell survival after oxidative damage,thus making CDKN1A/p21 a promising target for future drug discovery projects aimed at addressing the issue of therapeutic resistance and breast cancer metastasis.

Evangelos Manousakis;Cristina Moreta-Moraleda;Clàudia Martinez Miralles;Anna Tomàs Pujolà;Houda Baccara;Laia Liñán Franquet;Montserrat Montañés Albó;Roberto Ferrari;Roni H.G.Wright

Department of Biomedical Sciences,Faculty of Medicine and Health Sciences,Universitat Internacional de Catalunya(UIC),Barcelona,SpainDepartment of Biomedical Sciences,Faculty of Medicine and Health Sciences,Universitat Internacional de Catalunya(UIC),Barcelona,SpainDepartment of Biomedical Sciences,Faculty of Medicine and Health Sciences,Universitat Internacional de Catalunya(UIC),Barcelona,SpainDepartment of Biomedical Sciences,Faculty of Medicine and Health Sciences,Universitat Internacional de Catalunya(UIC),Barcelona,SpainDepartment of Chemistry,Life Sciences and Environmental Sustainability,University of Parma,Parma,ItalyDepartment of Biomedical Sciences,Faculty of Medicine and Health Sciences,Universitat Internacional de Catalunya(UIC),Barcelona,SpainDepartment of Biomedical Sciences,Faculty of Medicine and Health Sciences,Universitat Internacional de Catalunya(UIC),Barcelona,SpainDepartment of Chemistry,Life Sciences and Environmental Sustainability,University of Parma,Parma,ItalyDepartment of Biomedical Sciences,Faculty of Medicine and Health Sciences,Universitat Internacional de Catalunya(UIC),Barcelona,Spain

医药卫生

Breast cancer stem cells(BCSCs)CDKN1A/p21gene expressionchromatinoxidative damagespheroidtherapy resistance

《Oncology Research》 2026 (5)

P.478-500,23

supported by the“Ramon y Cajal”Fellowship(RYC2021-030923-I)awarded to R.W.,by the AIRC IG-2022 grant 27712 awarded to R.F.A.T.P was supported by AECC Summer Laboratory Practices 2024,PPLAB247653TOMA.

10.32604/or.2026.074965

评论